Praxis Precision Medicines, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Francois Brisebois from LifeSci Capital maintained a Buy rating on the stock and has a $383.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Francois Brisebois has given his Buy rating due to a combination of factors including the promising potential of Ulixacaltamide in addressing the unmet needs in the essential tremor market. The neurologist KOL’s optimism about Ulixacaltamide’s efficacy, especially in a subset of patients who may experience significant improvement, supports this positive outlook.
Furthermore, the manageable tolerability profile of Ulixacaltamide, which is viewed favorably compared to current standard treatments, suggests its potential for widespread use. The analyst anticipates that if approved, Ulixacaltamide could be tried in a substantial portion of practices, both as an add-on and monotherapy. Given the large market opportunity with many patients currently underserved by existing treatments, the commercial success of Ulixacaltamide appears promising, justifying the Buy rating.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is neutral on the stock.